Choisissez la langue de votre document :
- bg - български
- es - español
- cs - čeština
- da - dansk
- de - Deutsch
- et - eesti keel
- el - ελληνικά
- en - English (Selected)
- fr - français
- ga - Gaeilge
- hr - hrvatski
- it - italiano
- lv - latviešu valoda
- lt - lietuvių kalba
- hu - magyar
- mt - Malti
- nl - Nederlands
- pl - polski
- pt - português
- ro - română
- sk - slovenčina
- sl - slovenščina
- fi - suomi
- sv - svenska
| Parliamentary questions |
| |||
| 27 November 2019 |
| |||
| Answer given by Mr Andriukaitis on behalf of the European Commission | ||||
| Question reference: E-002981/2019 | ||||
The Commission is aware of the problem of shortages of essential medicinal products and its negative impact on the European patients. The Commission is following closely the issue and Member States’ and European Medicines Agency initiatives addressing this problem. The reasons of the shortages are diverse, and vary from the manufacturing issues to the commercial decisions of pharmaceutical industry. The current Commission is not in a position to answer questions related to the mandate of its successor and invites the Honourable Member of the European Parliament to address the question to the next Commission once it takes office. |
| Last updated: 4 December 2019 | Legal notice |